Hormonal Therapy for Acne

Seminars in Cutaneous Medicine and Surgery

Volumn 27, Issue 3, 2008, Pages 188-196

  George, Rosalyn ^a   Clarke, Shari ^a   Thiboutot, Diane ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DEXAMETHASONE; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENZYME INHIBITOR; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; GROWTH HORMONE; ISOTRETINOIN; MELANOCORTIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE SULFATE; PREDNISONE; PROGESTIN DROSPIRENONE; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAZ;

ACNE; ADRENAL SUPPRESSION; AMENORRHEA; ANDROGEN BLOOD LEVEL; BEDTIME DOSAGE; BIRTH DEFECT; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMINIZATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPOSPADIAS; HYPOTENSION; LETHARGY; LIBIDO; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; METRORRHAGIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PRESCRIPTION; PREVALENCE; REVIEW; SEBACEOUS GLAND; SIDE EFFECT; STROKE; THROMBOEMBOLISM; WEIGHT GAIN;

ACNE VULGARIS; ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL; CYPROTERONE ACETATE; FEMALE; FLUTAMIDE; HUMANS; SPIRONOLACTONE;

EID: 50949103523     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.06.002     Document Type: Review

References (84)

1. Collier C.N., Harper J.C., Cantrell W.C., et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 58 (2008) 56-59
2. Goulden V., Clark S.M., and Cunliffe W.J. Post-adolescent acne: Review of clinical features. Br J Dermatol 136 (1997) 66-70
3. Shaw J.C. Low dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 43 (2000) 498-502
4. Thiboutot D.M., Knaggs H., Gilliland K., et al. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 136 (1997) 166-171
5. Lucky A.W. Quantitative documentation of a premenstrual flare of facial acne in adult women. Arch Dermatol 140 (2004) 423-424
6. Thiboutot D., Gilliland K., Light J., et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 135 (1999) 1041-1045
7. Stewart M.E., Downing D.T., Cook J.S., et al. Sebaceous gland activity and serum dehydroepiandosterone sulfate levels in boys and girls. Arch Dermatol 128 (1992) 1345-1348
8. Lucky A.W., Biro F.M., Huster G.A., et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 130 (1994) 308-314
9. Imperato-McGinley J., Gautier T., Cai L.Q., et al. The androgen control of sebum production: Studies on subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metabol 76 (1993) 524-528
10. Choudhry R., Hodgins M.B., Van der Kwast T.H., et al. Localization of androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 133 (1992) 467-475
11. Liang T, Hoyer S, Yu R, et al: Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 100663-100666, 199
12. Simpton N.B., Cunliffe W.J., and Hodgins M.B. The relationship between the vitro activity of 3 beta-hydroxysteroid dehydrogenase delta 4-5-isomerase in human sebaceous glands and their secretory activity in vivo. J Invest Dermatol 81 (1983) 139-144
13. Mason J. The 3β-hydroxysteroid dehydrogenase gene family of enzymes. Trends Endocrin Metab 4 (1993) 199-202
14. Thiboutot D., Martin P., Volikos L., et al. Oxidative activity of the type 2 isozyme of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) predominates in human sebaceous glands. J Invest Dermatol 111 (1998) 390-395
15. Thiboutot D., Harris G., Iles V., et al. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 105 (1995) 209-214
16. Strauss J.S., and Pochi P.E. Effect of cyclic progestin-estrogen therapy on sebum and acne in women. JAMA 190 (1964) 815-819
17. Rosenfield R.L., and Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 98 (1995) 80S-88S
18. Zouboulis C.C., Xia L., Akamatsu H., et al. The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology 196 (1998) 21-31
19. Chen W., Kelly M.A., Opitz-Araya X., et al. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 91 (1997) 789-798
20. van der Kraan M., Adan R.A., Entwistle M.L., et al. Expression of melanocortin-5 receptor in secretory epithelia supports functional role in exocrine and endocrine glands. Endocrinology 139 (1998) 2348-2355
21. Thiboutot D., Sivarajah A., Gilliland K., et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol 115 (2000) 614-619
22. Hatta N., Dixon C., Ray A.J., et al. Expression, candidate gene, and population studies of the melanocortin 5 receptor. J Invest Dermatol 116 (2001) 564-570
23. Tremblay M.R., Luu-The V., Leblanc G., et al. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg Med Chem 7 (1999) 1013-1023
24. Archer J.S., and Chang R.J. Hirsutism and acne in polycystic ovarian syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 737-754
25. Zouboulis C.C., Akamatsu H., Stephanek K., et al. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol 7 (1994) 33-40
26. Thiboutot D., and Chen W. Update and future of hormonal therapy in acne. Dermatology 206 (2003) 57-67
27. Goodfellow A., Alaghband-Zadeh J., Carter G., et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 111 (1984) 209-214
28. Burke B.M., and Cunliffe W.J. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 112 (1985) 124-125
29. Muhlemann M.F., Carter G.D., Cream J.J., et al. Oral spironolactone: An effective treatment for acne vulgaris in women. Br J Dermatol 115 (1986) 227-232
30. Hatwal A., Bhatt R.P., Agrawal J.C., et al. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol 68 (1988) 84-87
31. Shaw J.C. Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 43 (2000) 498-502
32. Yemisci A., Gorgulu A., and Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 19 (2005) 163-166
33. Lubbos H.G., Hasinski S., Rose L.I., et al. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 134 (1998) 1162-1163
34. Krunic A., Ciurea A., and Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 58 (2008) 60-62
35. Shaw J.C. Spironolactone in dermatologic therapy. J Am Acad Dermatol 24 (1991) 236-243
36. Tóth I., Szécsi M., Julesz J., et al. Activity and inhibition of 3-beta-ydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin. Skin Pharmacol 10 (1997) 160-168
37. Dumont M., Luu-The V., Dupont E., et al. Characterization expression, and immunohistochemical localisation of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in human skin. J Invest Dermatol 99 (1992) 415-421
38. Van Waygen R., and Van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate containing preparations. Exp Clin Endocrinol Diabetes 103 (1995) 241-251
39. Tan J. Hormonal treatment of acne: Review of current best evidence. J Cutan Med Surg 8 suppl 4 (2005) 11-15
40. Stewart M.E. Effect of cyproterone actetate-ethyinly estradiol treatment on the proportions of linoleic and sebaleic acids in various skin surface lipid classes. Arch Dermatol Res 278 (1986) 481-485
41. Zouboulis C.C., and Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 206 (2003) 37-53
42. Carmina E., and Lobo R.A.A. Comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 57 (2002) 231-234
43. van Vloten W.A., van Haselen C.W., van Zuuren E.J., et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69 suppl 4 (2002) 2-15
44. Carlborg L. Cyproterone acetate vs levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand Suppl 134 (1986) 29-32
45. Giordano N. Acute hepatitis induced by cyproterone acetate. Ann Pharmcother 35 (2001) 1053-1055
46. Franks S., Layton A., and Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod 23 (2008) 231-232
47. Shaw J.C. Acne: Effect of hormones on pathogenesis and management. Am J Clin Dermatol 3 (2002) 571-578
48. Cusan L., Dupont A., Bélanger A., et al. Treatment of hirsutism with the pure anti-androgen flutamide. J Am Acad Dermatol 23 (1990) 462-469
49. Wang H.S., Wang T.H., and Soong Y.K. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi 22 (1999) 423-432
50. Cusan L., Dupont A., Gomez J.L., et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril 61 (1994) 281-287
51. Müderris I.I., Bayram F., and Güven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14 (2000) 38-41
52. Wysowski D.K., Freiman J.P., Tourtelot J.B., et al. Fatal and nonfatal hepatotoxicity associated with flutamide Ann Intern Med 118 (1993) 860-864
53. Garcia Cortes M., Andrade R.J., Lucena M.I., et al. Flutamide-induced hepatotoxicity: A report of a case series. Rev Enferm Dig 93 (2001) 423-432
54. Dodin S., Faure N., Cédrin I., et al. Clinical efficacy and safety of low dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol 43 (1995) 575-582
55. Faloia E., Filipponi S., Mancini V., et al. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J Endocrinol Invest 16 (1993) 675-677
56. Petitti D.B., Sidney S., Bernstein A., et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 335 (1996) 8-15
57. Mant J., Painter R., and Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: An updated analysis of a cohort study. Br J Obstet Gynaecol 105 (1998) 890-896
58. Speroff L., and DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 81 (1993) 1034-1047
59. Thorneycroft I. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 47 suppl 11 (2002) 975-980
60. Greenwood R., Brummitt L., Burke B., et al. Acne: Double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 291 (1985) 1231-1235
61. Lemay A., Dewailly S.D., Grenier R., et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab 71 (1990) 8-14
62. Lucky A.W., Henderson T.A., Olson W.H., et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37 (1997) 746-754
63. Redmond G.P., Olson W.H., Lippman J.S., et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet Gynecol 89 (1997) 615-622
64. Thiboutot D., Archer D.F., Lemay A., et al. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 76 (2001) 461-468
65. Leyden J., Shalita A., Hordinsky M., et al. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol 47 (2002) 399-409
66. Maloney M., Arbit D., Flack M., et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health 1 (2001) 124-131
67. Bilotta P., and Favilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Drug Res 38 (1988) 932-935
68. Dinger J.C., Heinemann L.A., and Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
69. Pehlivanov B., and Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 12 (2007) 30-35
70. De Leo V., Morgante G., Piomboni P., et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 88 (2007) 113-117
71. th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, May 5-9, 2007, San Diego, CA
72. th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, May (2007) 5-9 San Diego, CA
73. Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 77 (2008) 249
74. Pasekova V., and Chroust K. Occurrence of bleeding in women using combined hormonal contraceptives (ethinylestradiol 35 micrograms/norgestimate 250 micrograms) in relation to regularity of administration and cycle start day. Ceska Gynekol 68 (2003) 84
75. Lara-Torre E., and Schroeder B. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. Contraception 66 (2002) 81
76. Westhoff C., Kerns J., Morroni C., et al. Quick Start: A novel oral contraceptive initiation method. Contraception 66 (2002) 141
77. Westhoff C., Morroni C., Kerns J., et al. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril 79 (2003) 322
78. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,237 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
79. ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 10 (2004) 281-293
80. Archer J., and Archer D. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 6 (2002) 917-923
81. Weaver K., and Glasier A. Interaction between broad spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 59 (1999) 71-78
82. Helms S.E., Bredle D.L., Zajic J., et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 36 (1997) 705-710
83. London B.M., and Lookingbill D.P. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives [letter]. Arch Dermatol 130 (1994) 392-393
84. Gisleskog P., et al. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 64 (1998) 636-647